This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Donnelly, S. M Articles by Miller, J. A Search for Related Content PubMed PubMed Citation Articles by Donnelly, S. M Articles by Miller, J. A Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Hazardous Substances DB LOSARTAN POTASSIUM SODIUM Social Bookmarking                         What's this?

Losartan may modulate erythropoietin production

St. Michael's Hospital, 61 Queen Street East, 7-033 Toronto, Ontario, Canada, sandra.donnelly @utoronto.ca

Judith A Miller

St. Michael's Hospital, 61 Queen Street East, 7-033 Toronto, Ontario, Canada

Erythropoietin (Epo) is distinct amongst haematopoietic hormones, in that it is produced remote from the bone marrow. The tissue oxygen pressure required to trigger the Epo gene under physiological conditions is uniquely sited at a restricted area in the kidney termed the critmeter. Angiotensin II (Ang II) increases sodium reabsorption and hence oxygen consumption at any given blood flow rate; therefore, it may affect the balance of renal oxygen supply vs. demand and hence Epo production. The purpose of this study was to determine whether Epo production is modulated by the renin-angiotensin system (RAS). Twenty normal subjects on a controlled sodium and protein diet had glomerular filtration rate (GFR) and renal plasma flow (RPF) assessed by standard methods of inulin and para-aminohippurate clearance, respectively, at baseline, hourly after the administration of losartan (25 mg) and after each 30 minute period of the infusion of Ang II at doses of 0.5, 1.5 and 2.5 ng/kg/minute. The baseline GFR was 115±4.0 ml/minute/1.73 m², RPF 650±29 ml/minute/1.73 m² and Epo 12.4±0.8 U/L. In spite of a marked increase in filtration fraction (FF) with Ang II, no changes in serum Epo levels were observed at two hours (11.7±1.3 U/L, p=n.s. compared with baseline). After the administration of losartan, there was a variable effect on FF, but a strong correlation of the change in serum Epo concentration and the change in FF (r=0.648, p=0.002), suggesting that the RAS may modulate Epo production.

Key Words: erythropoietin • angiotensin II • filtration fraction • losartan • renin-angiotensin system

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 4, 255-260 (2001)
DOI: 10.3317/jraas.2001.040


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Lundby, J. J. Thomsen, R. Boushel, M. Koskolou, J. Warberg, J. A. L. Calbet, and P. Robach Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume J. Physiol., January 1, 2007; 578(1): 309 - 314. [Abstract] [Full Text] [PDF]

				S. R. Raj, I. Biaggioni, P. C. Yamhure, B. K. Black, S. Y. Paranjape, D. W. Byrne, and D. Robertson Renin-Aldosterone Paradox and Perturbed Blood Volume Regulation Underlying Postural Tachycardia Syndrome Circulation, April 5, 2005; 111(13): 1574 - 1582. [Abstract] [Full Text] [PDF]